Neutralizing Antibodies against Lassa Virus Lineage I-Reference-Cited by-同舟云学术

Neutralizing Antibodies against Lassa Virus Lineage I

Published:2022-08-30 Issue:4 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Buck Tierra K.¹,Enriquez Adrian S.¹,Schendel Sharon L.¹,Zandonatti Michelle A.¹,Harkins Stephanie S.¹,Li Haoyang¹,Moon-Walker Alex¹²³,Robinson James E.⁴,Branco Luis M.⁵,Garry Robert F.⁵⁶,Saphire Erica Ollmann¹^ORCID,Hastie Kathryn M.¹

Affiliation:

1. La Jolla Institute for Immunology, La Jolla, California, USA

2. Program in Virology, Harvard University, Boston, Massachusetts, USA

3. Department of Molecular Microbiology, Washington University in Saint Louis, St. Louis, Missouri, USA

4. Department of Pediatrics, Tulane University School of Medicine, New Orleans, Louisiana, USA

5. Zalgen Labs, LLC, Germantown, Maryland, USA

6. Department of Microbiology and Immunology, Tulane University School of Medicine, New Orleans, Louisiana, USA

Abstract

No vaccine or therapeutics are approved to prevent LASV infection or treat LF. All vaccine platforms currently under development present only the LIV GP sequence.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.01278-22

Reference49 articles.

1. Lassa Fever

2. Lassa Fever in Post-Conflict Sierra Leone

3. A Prospective Study of the Epidemiology and Ecology of Lassa Fever